UNSPSC 51152100: Combination antimuscarinic and antipasmodics

This classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term ANTIMUSCARINICS. Antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system.

Typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.

UNSPSC 51152100 Combination antimuscarinic and antispasmodics, a Class code, sees minimal alignment with recent state and local procurement activity. The two most recent opportunities posted under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI regarding direct-to-manufacturer prescription programs—fall outside the scope of combination antimuscarinic and antispasmodic pharmaceuticals that the code nominally describes. The Seminole County solicitation targets emergency-response and harm-reduction supplies rather than gastrointestinal or urinary antispasmodic medications, while the Texas HHS RFI addresses pharmacy benefit program architecture and direct contracting with manufacturers across a broad pharmaceutical spectrum, not a specific drug class. The code shows little relevant recent activity in its stated domain.

No state or local procurement opportunities directly soliciting combination antimuscarinic and antispasmodic products appear in the available records. The geographic and issuing-body patterns in the source—Florida counties and state health commissions—do not establish a meaningful market signal for this specific pharmaceutical class at the state and local level.